Latest News for: taiho

Edit

Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at ...

St Albans Messenger 09 Dec 2025
Two oral presentations will highlight Phase 2 results from ...
Edit

Taiho Oncology Presents Data on All-Oral Regimens Azacitidine and Cedazuridine, and Decitabine and Cedazuridine at the 2025 American Society of Hematology Annual Meeting and Exposition

PR Newswire 08 Dec 2025
About Taiho Oncology, Inc. The mission of Taiho Oncology, Inc ... Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd ... Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd ... SOURCE Taiho Oncology.
Edit

Taiho Oncology Europe announces the launch of Lytgobi®▼ (futibatinib) in the United Kingdom for eligible ...

Business Wire 03 Dec 2025
BAAR, Switzerland--(BUSINESS WIRE)--For United Kingdom (UK) Trade and Medical Media Only Taiho ...
Edit

Taiho Oncology Europe announces the launch of Lytgobi®▼ (futibatinib) in the United Kingdom for eligible adult patients with a previously treated subtype of locally advanced or metastatic cholangiocarcinoma1

Pharmiweb 03 Dec 2025
Lytgobi (futibatinib) marks the first medicine launched by Taiho Oncology Europe in the UK2 ... Peter Foertig, General Manager of Taiho Oncology Europe ... The larger Taiho family of companies continues to investigate its potential in other tumours.12.
Edit

JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information (NEC Corporation)

Public Technologies 28 Nov 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 128016808) .
Edit

JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information

JCN Newswire 28 Nov 2025
TOKYO, Nov 28, 2025 - (JCN Newswire) - The Japanese Foundation for Cancer Research (JFCR), NEC Corporation (NEC), and Taiho Pharmaceutical Co., Ltd ... About Taiho Pharmaceutical Co., Ltd. Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd.
Edit

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

PR Newswire 20 Nov 2025
20, 2025 /PRNewswire/ -- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc ... Taiho Pharmaceutical ... Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd ... Taiho Oncology.
Edit

Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (Cullinan Therapeutics Inc)

Public Technologies 20 Nov 2025
20, 2025 - Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc ... About Taiho Oncology, Inc ... Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd.
Edit

Taiho Oncology Announces 14 Presentations, Including Six Oral Presentations, at the 67th American Society of ...

Biltmore Beacon 14 Nov 2025
Six oral presentations will detail new data on the ...
Edit

Taiho Oncology Announces 14 Presentations, Including Six Oral Presentations, at the 67th American Society of Hematology Annual Meeting and Exposition

PR Newswire 13 Nov 2025
Taiho Oncology will share findings from clinical trials in two oral presentations and evidence from real-world studies in two online abstracts ... Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd.
Edit

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories ...

The Galveston Daily News 20 Oct 2025
TOKYO & HAYWARD, Calif.--(BUSINESS WIRE)--Oct 19, 2025-- ....
Edit

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

Pharmiweb 20 Oct 2025
TOKYO & HAYWARD, Calif.--(BUSINESS WIRE)--Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc ... This option exercise is based on a 2017 option and license agreement between Taiho and Arcus ... About the Taiho and Arcus Agreement.
Edit

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR ...

The Eagle-Tribune 13 Oct 2025
12, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and ...
Edit

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025

PR Newswire 12 Oct 2025
About Taiho Oncology, Inc.The mission of Taiho Oncology, Inc ... Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd ... Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd ... Taiho Oncology.
Edit

Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR Mutations and Active Brain Metastases at the ESMO Congress 2025 (Cullinan Therapeutics Inc)

Public Technologies 12 Oct 2025
About Taiho Oncology, Inc. The mission of Taiho Oncology, Inc ... Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd ... Taiho Oncology and the Taiho Oncology logo are registered trademarks of Taiho Pharmaceutical Co., Ltd ... Taiho Oncology.

Article Search

tools
×
×
×
×